{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:43:46Z","timestamp":1793040226398,"version":"4.5.0"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Isolated rapid eye movement sleep (REM) behavior disorder (iRBD) represents the strongest predictor of \u03b1-synucleinopathies, with over 90% of patients developing Parkinson\u2019s disease, dementia with Lewy bodies, or multiple system atrophy after a decade. As such, iRBD provides a critical window for early diagnosis and intervention. While molecular imaging techniques have been widely explored as powerful biomarkers for early disease detection, validated, more accessible tests based on biospecimens capable of reliably predicting phenoconversion remain lacking, creating a crucial gap in the clinical management of at-risk individuals. This review provides a critical overview of the latest findings in biofluid and tissue-based biomarkers in iRBD, emphasizing the most promising candidates and outlining key directions for future research and clinical applications. While cerebrospinal fluid (CSF)-based \u03b1-synuclein has widely proven high diagnostic and prognostic accuracy, blood, urine, stool, skin, olfactory, and oral mucosa samples offer a feasible approach for scalable, population-level screenings in prodromal \u03b1-synucleinopathies. The development of multimodal biomarker panels combining accessible biofluids and tissue samples may pave the way for early intervention and more effective risk stratification in future neuroprotective trials for \u03b1-synucleinopathies.<\/jats:p>\n                  <jats:p>Statement of Significance This review provides an up-to-date synthesis of the most recent and high-impact studies on biomarkers in isolated rapid eye movement sleep (REM) sleep behavior disorder (iRBD). The growing emphasis on the applicability of less invasive and more clinically accessible biofluids and peripheral tissues reflects a broader clinical shift toward noninvasive approaches capable of supporting population-level screening and targeted interventions. Currently, no validated laboratory tests exist in clinical practice to reliably predict iRBD phenoconversion to overt \u03b1-synucleinopathies, creating a critical gap in early stage disease management. The insights presented here will be essential for developing early diagnostic tools and refining patient stratification strategies, both of which are essential for upcoming disease-modifying trials targeting early stage \u03b1-synucleinopathies.<\/jats:p>","DOI":"10.1093\/sleep\/zsaf174","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T07:54:00Z","timestamp":1750319640000},"source":"Crossref","is-referenced-by-count":14,"title":["Tracking prodromal \u03b1-synucleinopathies: novel fluid- and tissue-based biomarker approaches for iRBD phenoconversion"],"prefix":"10.1093","volume":"48","author":[{"given":"Giulia","family":"Bruschi","sequence":"first","affiliation":[{"name":"Department of Psychology, Vita-Salute San Raffaele University , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bortolin","sequence":"additional","affiliation":[{"name":"Department of Psychology, Vita-Salute San Raffaele University , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5985-5060","authenticated-orcid":false,"given":"Salvatore","family":"Mazzeo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vita-Salute San Raffaele University , Milan ,","place":["Italy"]},{"name":"Neurology unit, IRCCS Policlinico San Donato , San Donato Milanese ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bombaci","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vita-Salute San Raffaele University , Milan ,","place":["Italy"]},{"name":"Neurology unit, IRCCS Policlinico San Donato , San Donato Milanese ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico Emanuele","family":"Pozzi","sequence":"additional","affiliation":[{"name":"Neurology unit, IRCCS Policlinico San Donato , San Donato Milanese ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-4979","authenticated-orcid":false,"given":"Federica","family":"Agosta","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vita-Salute San Raffaele University , Milan ,","place":["Italy"]},{"name":"Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service , IRCCS Ospedale San Raffaele Hospital, Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Ferini-Strambi","sequence":"additional","affiliation":[{"name":"Department of Psychology, Vita-Salute San Raffaele University , Milan ,","place":["Italy"]},{"name":"Department of Neurology, Vita-Salute San Raffaele University , Milan ,","place":["Italy"]},{"name":"Department of Clinical Neurosciences, Neurology-Sleep Disorders Center, IRCCS San Raffaele Scientific Institute , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vita-Salute San Raffaele University , Milan ,","place":["Italy"]},{"name":"Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service , IRCCS Ospedale San Raffaele Hospital, Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Salsone","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vita-Salute San Raffaele University , Milan ,","place":["Italy"]},{"name":"Neurology unit, IRCCS Policlinico San Donato , San Donato Milanese ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"issue":"1","key":"2025121103123462600_ref1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41572-018-0016-5","article-title":"REM sleep behaviour disorder","volume":"4","author":"Dauvilliers","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2025121103123462600_ref2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/brain\/awz030","article-title":"Risk and predictors of dementia and Parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study","volume":"142","author":"Postuma","year":"2019","journal-title":"Brain."},{"issue":"12","key":"2025121103123462600_ref3","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S1474-4422(24)00402-2","article-title":"Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series","volume":"23","author":"May\u00e0","year":"2024","journal-title":"Lancet Neurol"},{"issue":"2","key":"2025121103123462600_ref4","doi-asserted-by":"publisher","first-page":"e89741","DOI":"10.1371\/journal.pone.0089741","article-title":"Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients","volume":"9","author":"Iranzo","year":"2014","journal-title":"PLoS One"},{"key":"2025121103123462600_ref5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.smrv.2018.09.008","article-title":"The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies","volume":"43","author":"Galbiati","year":"2019","journal-title":"Sleep Med Rev"},{"issue":"12","key":"2025121103123462600_ref6","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"MDS research criteria for prodromal Parkinson\u2019s disease","volume":"30","author":"Berg","year":"2015","journal-title":"Mov Disord"},{"issue":"10","key":"2025121103123462600_ref7","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.27802","article-title":"Update of the MDS research criteria for prodromal Parkinson\u2019s disease","volume":"34","author":"Heinzel","year":"2019","journal-title":"Mov Disord"},{"issue":"2","key":"2025121103123462600_ref8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/ana.25952","article-title":"Timeline of rapid eye movement sleep behavior disorder in overt alpha-Synucleinopathies","volume":"89","author":"Stang","year":"2021","journal-title":"Ann Neurol"},{"issue":"8","key":"2025121103123462600_ref9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1474-4422(21)00176-9","article-title":"Biomarkers of conversion to \u03b1-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder","volume":"20","author":"Miglis","year":"2021","journal-title":"Lancet Neurol"},{"issue":"11","key":"2025121103123462600_ref10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/14737175.2019.1640603","article-title":"Neuropsychological, electrophysiological, and neuroimaging biomarkers for REM behavior disorder","volume":"19","author":"Ferini-Strambi","year":"2019","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"2025121103123462600_ref11","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/brain\/awac115","article-title":"Detection of neuron-derived pathological \u03b1-synuclein in blood","volume":"145","author":"Kluge","year":"2022","journal-title":"Brain"},{"issue":"1","key":"2025121103123462600_ref12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41531-022-00431-7","article-title":"A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson\u2019s disease","volume":"8","author":"Xiang","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"issue":"3","key":"2025121103123462600_ref13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3233\/JPD-201983","article-title":"Detection and assessment of \u03b1-synuclein oligomers in the urine of Parkinson\u2019s disease patients","volume":"10","author":"Nam","year":"2020","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"2025121103123462600_ref14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40035-022-00311-3","article-title":"Olfactory swab sampling optimization for \u03b1-synuclein aggregate detection in patients with Parkinson\u2019s disease","volume":"11","author":"Bongianni","year":"2022","journal-title":"Transl Neurodegener"},{"issue":"5","key":"2025121103123462600_ref15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3233\/JPD-230065","article-title":"Seed amplification assay as a diagnostic tool in newly-diagnosed Parkinson\u2019s disease","volume":"13","author":"Oftedal","year":"2023","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"2025121103123462600_ref16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/mds.27897","article-title":"CSF or serum neurofilament light added to \u03b1-synuclein panel discriminates Parkinson\u2019s from controls","volume":"35","author":"Oosterveld","year":"2020","journal-title":"Mov Disord"},{"issue":"1","key":"2025121103123462600_ref17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-023-00374-w","article-title":"Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson\u2019s disease","volume":"12","author":"Paslawski","year":"2023","journal-title":"Transl Neurodegener"},{"issue":"s2","key":"2025121103123462600_ref18","doi-asserted-by":"publisher","first-page":"S323","DOI":"10.3233\/JPD-230429","article-title":"Biofluid detection of pathological \u03b1 -synuclein in the prodromal phase of Synucleinopathies","volume":"14","author":"Kluge","year":"2024","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"2025121103123462600_ref19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00401-024-02706-0","article-title":"Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson\u2019s disease","volume":"147","author":"Rutledge","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2025121103123462600_ref20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40035-024-00421-0","article-title":"DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson\u2019s disease","volume":"13","author":"Appleton","year":"2024","journal-title":"Transl Neurodegener"},{"issue":"2","key":"2025121103123462600_ref21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mds.26479","article-title":"Synaptic failure and \u03b1-synuclein","volume":"31","author":"Calo","year":"2016","journal-title":"Mov Disord"},{"issue":"5","key":"2025121103123462600_ref22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1212\/WNL.0000000000200878","article-title":"\u0391-synuclein seed amplification assays for diagnosing synucleinopathies","volume":"99","author":"Bellomo","year":"2022","journal-title":"Neurology."},{"issue":"10","key":"2025121103123462600_ref23","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-Qu IC in the CSF of patients with alpha-synucleinopathies","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"2025121103123462600_ref24","doi-asserted-by":"publisher","first-page":"105807","DOI":"10.1016\/j.parkreldis.2023.105807","article-title":"\u0391-synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders","volume":"117","author":"Fernandes Gomes","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"2025121103123462600_ref25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies","volume":"140","author":"Rossi","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2025121103123462600_ref26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s40478-021-01282-8","article-title":"High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease","volume":"9","author":"Russo","year":"2021","journal-title":"Acta Neuropathol Commun"},{"issue":"10","key":"2025121103123462600_ref27","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1002\/mds.28715","article-title":"Seed amplification assay to diagnose early Parkinson\u2019s and predict dopaminergic deficit progression","volume":"36","author":"Concha-Marambio","year":"2021","journal-title":"Mov Disord"},{"issue":"18","key":"2025121103123462600_ref28","doi-asserted-by":"publisher","first-page":"e1944","DOI":"10.1212\/WNL.0000000000207147","article-title":"Misfolded \u03b1-synuclein assessment in the skin and CSF by RT-QuIC in isolated REM sleep behavior disorder","volume":"100","author":"Iranzo","year":"2023","journal-title":"Neurology"},{"issue":"5","key":"2025121103123462600_ref29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson\u2019s progression markers initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurol"},{"issue":"4","key":"2025121103123462600_ref30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/mds.29329","article-title":"Accurate detection of \u03b1-synuclein seeds in cerebrospinal fluid from isolated rapid eye movement sleep behavior disorder and patients with Parkinson\u2019s disease in the DeNovo Parkinson (DeNoPa) cohort","volume":"38","author":"Concha-Marambio","year":"2023","journal-title":"Mov Disord"},{"issue":"2","key":"2025121103123462600_ref31","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/brain\/awab431","article-title":"Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies","volume":"145","author":"Poggiolini","year":"2022","journal-title":"Brain."},{"issue":"3","key":"2025121103123462600_ref32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","article-title":"Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study","volume":"20","author":"Iranzo","year":"2021","journal-title":"Lancet Neurol"},{"issue":"1","key":"2025121103123462600_ref33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41531-024-00770-7","article-title":"CSF markers of neurodegeneration Alzheimer\u2019s and Lewy body pathology in isolated REM sleep behavior disorder","volume":"10","author":"Mu\u00f1oz-Lopetegi","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"issue":"6","key":"2025121103123462600_ref34","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","article-title":"Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies","volume":"29","author":"Okuzumi","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"2025121103123462600_ref35","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/biosci\/biv084","article-title":"Extracellular vesicles: composition, biological relevance, and methods of study","volume":"65","author":"Zaborowski","year":"2015","journal-title":"Bioscience"},{"issue":"1","key":"2025121103123462600_ref36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"2025121103123462600_ref37","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/mds.29497","article-title":"Extracellular vesicles for the diagnosis of Parkinson\u2019s disease: systematic review and meta-analysis","volume":"38","author":"Xylaki","year":"2023","journal-title":"Mov Disord"},{"issue":"12","key":"2025121103123462600_ref38","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1111\/ene.15537","article-title":"Different patterns of exosomal \u03b1-synuclein between Parkinson\u2019s disease and probable rapid eye movement sleep behavior disorder","volume":"29","author":"Yan","year":"2022","journal-title":"Eur J Neurol"},{"issue":"1","key":"2025121103123462600_ref39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamaneurol.2023.4398","article-title":"Neuronally derived extracellular vesicle \u03b1-synuclein as a serum biomarker for individuals at risk of developing Parkinson disease","volume":"81","author":"Yan","year":"2023","journal-title":"JAMA Neurol"},{"issue":"8","key":"2025121103123462600_ref40","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/mds.29766","article-title":"Detecting misfolded \u03b1-synuclein in blood years before the diagnosis of Parkinson\u2019s disease","volume":"39","author":"Kluge","year":"2024","journal-title":"Mov Disord"},{"issue":"s2","key":"2025121103123462600_ref41","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.3233\/JPD-191721","article-title":"Brain-first versus gut-first Parkinson\u2019s disease: a hypothesis","volume":"9","author":"Borghammer","year":"2019","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"2025121103123462600_ref42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1101\/2025.01.14.25320280","article-title":"Elevated \u03b1-synuclein aggregate levels in the urine of patients with isolated REM sleep behavior disorder and Parkinson\u2019s disease","volume":"98","author":"M\u00fcller","year":"2025","journal-title":"Ann Neurol"},{"issue":"1","key":"2025121103123462600_ref43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41531-023-00458-4","article-title":"Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool","volume":"9","author":"Schaffrath","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"2025121103123462600_ref44","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/brain\/awab005","article-title":"Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder","volume":"144","author":"Stefani","year":"2021","journal-title":"Brain"},{"issue":"8","key":"2025121103123462600_ref45","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/mds.29828","article-title":"Detection of \u03b1-synuclein in oral mucosa by seed amplification assay in Synucleinopathies and isolated REM sleep behavior disorder","volume":"39","author":"Zheng","year":"2024","journal-title":"Mov Disord"},{"issue":"1","key":"2025121103123462600_ref46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41531-023-00519-8","article-title":"Combining skin and olfactory \u03b1-synuclein seed amplification assays (SAA)\u2014towards biomarker-driven phenotyping in synucleinopathies","volume":"9","author":"Kuzkina","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"issue":"7","key":"2025121103123462600_ref47","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1093\/brain\/awt152","article-title":"The coeruleus\/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson\u2019s disease","volume":"136","author":"Garc\u00eda-Lorenzo","year":"2013","journal-title":"Brain"},{"issue":"5","key":"2025121103123462600_ref48","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.neuron.2016.07.036","article-title":"High-throughput mapping of single-neuron projections by sequencing of barcoded RNA","volume":"91","author":"Kebschull","year":"2016","journal-title":"Neuron"},{"issue":"1-2","key":"2025121103123462600_ref49","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0006-8993(85)90537-2","article-title":"Surprisingly rich projection from locus coeruleus to the olfactory bulb in the rat","volume":"329","author":"Shipley","year":"1985","journal-title":"Brain Res"},{"key":"2025121103123462600_ref50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fnagi.2022.867528","article-title":"Oral mucosa derived \u03b1\u2212synuclein as a potential diagnostic biomarker for Parkinson\u2019s disease","volume":"14","author":"Zheng","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"20","key":"2025121103123462600_ref51","doi-asserted-by":"publisher","first-page":"e2513","DOI":"10.1212\/WNL.0000000000011935","article-title":"In vivo diagnosis of synucleinopathies","volume":"96","author":"Donadio","year":"2021","journal-title":"Neurology."},{"issue":"1","key":"2025121103123462600_ref52","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaneurol.2020.3311","article-title":"Skin \u03b1-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease","volume":"78","author":"Wang","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"2025121103123462600_ref53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41531-023-00473-5","article-title":"A comparative blind study between skin biopsy and seed amplification assay to disclose pathological \u03b1-synuclein in RBD","volume":"9","author":"Liguori","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"2025121103123462600_ref54","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.parkreldis.2021.04.007","article-title":"Consistent skin \u03b1-synuclein positivity in REM sleep behavior disorder \u2013 a two center two-to-four-year follow-up study","volume":"86","author":"Doppler","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"2025121103123462600_ref55","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/mds.28399","article-title":"Immunohistochemical detection of synuclein pathology in skin in idiopathic rapid eye movement sleep behavior disorder and parkinsonism","volume":"36","author":"Al-Qassabi","year":"2021","journal-title":"Mov Disord"},{"issue":"1","key":"2025121103123462600_ref56","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00401-023-02663-0","article-title":"Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden","volume":"147","author":"Bentivenga","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2025121103123462600_ref57","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3233\/JPD-223519","article-title":"Neurofilament light protein predicts disease progression in idiopathic REM sleep behavior disorder","volume":"13","author":"Zhang","year":"2023","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"2025121103123462600_ref58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuron.2016.06.030","article-title":"Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration","volume":"91","author":"Zetterberg","year":"2016","journal-title":"Neuron"},{"issue":"12","key":"2025121103123462600_ref59","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/mds.28779","article-title":"Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease","volume":"36","author":"Aamodt","year":"2021","journal-title":"Mov Disord"},{"issue":"1","key":"2025121103123462600_ref60","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41531-021-00232-4","article-title":"Neurofilament light chain and \u03b1-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes","volume":"7","author":"Quadalti","year":"2021","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"2025121103123462600_ref61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1212\/WNL.0000000000008088","article-title":"Blood NfL","volume":"93","author":"Lin","year":"2019","journal-title":"Neurology"},{"issue":"13","key":"2025121103123462600_ref62","doi-asserted-by":"publisher","first-page":"e1479","DOI":"10.1212\/WNL.0000000000007179","article-title":"Serum NFL discriminates Parkinson disease from atypical parkinsonisms","volume":"92","author":"Marques","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"2025121103123462600_ref63","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/mds.28206","article-title":"Validation of serum neurofilament light chain as a biomarker of Parkinson\u2019s disease progression","volume":"35","author":"Mollenhauer","year":"2020","journal-title":"Mov Disord"},{"key":"2025121103123462600_ref64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.parkreldis.2021.02.008","article-title":"Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson\u2019s disease: an 8-year longitudinal study","volume":"85","author":"Ye","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"2025121103123462600_ref65","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1007\/s00415-023-11785-0","article-title":"Neurofilament light chain and cardiac MIBG uptake as predictors for phenoconversion in isolated REM sleep behavior disorder","volume":"270","author":"Park","year":"2023","journal-title":"J Neurol"},{"issue":"1","key":"2025121103123462600_ref66","doi-asserted-by":"publisher","first-page":"e16089","DOI":"10.1111\/ene.16089","article-title":"Plasma neurofilament light chain predicts Alzheimer\u2019s disease in patients with subjective cognitive decline and mild cognitive impairment: a cross-sectional and longitudinal study","volume":"31","author":"Mazzeo","year":"2023","journal-title":"Eur J Neurol"},{"issue":"4","key":"2025121103123462600_ref67","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac174","article-title":"Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5\u201390 years","volume":"4","author":"Simr\u00e9n","year":"2022","journal-title":"Brain Commun"},{"issue":"10","key":"2025121103123462600_ref68","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s43587-023-00478-y","article-title":"DOPA decarboxylase is an emerging biomarker for parkinsonian disorders including preclinical Lewy body disease","volume":"3","author":"Pereira","year":"2023","journal-title":"Nat Aging"},{"issue":"1","key":"2025121103123462600_ref69","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/s41467-025-56293-z","article-title":"Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment","volume":"16","author":"Bolsewig","year":"2025","journal-title":"Nat Commun"},{"issue":"8","key":"2025121103123462600_ref70","doi-asserted-by":"publisher","DOI":"10.3390\/antiox8080265","article-title":"Astrocytic oxidative\/nitrosative stress contributes to parkinson\u2019s disease pathogenesis: the dual role of reactive astrocytes","volume":"8","author":"Rizor","year":"2019","journal-title":"Antioxidants"},{"issue":"5","key":"2025121103123462600_ref71","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00401-006-0119-z","article-title":"Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration","volume":"112","author":"Croisier","year":"2006","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2025121103123462600_ref72","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/alz.13653","article-title":"Plasma biomarkers of Alzheimer\u2019s disease in the continuum of dementia with Lewy bodies","volume":"20","author":"Diaz-Galvan","year":"2024","journal-title":"Alzheimer\u2019s and Dementia"},{"issue":"12","key":"2025121103123462600_ref73","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1007\/s00415-024-12669-7","article-title":"Plasma NfL, GFAP, amyloid, and p-tau species as prognostic biomarkers in Parkinson\u2019s disease","volume":"271","author":"Pilotto","year":"2024","journal-title":"J Neurol"},{"issue":"1","key":"2025121103123462600_ref74","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41531-023-00447-7","article-title":"Plasma GFAP in Parkinson\u2019s disease with cognitive impairment and its potential to predict conversion to dementia","volume":"9","author":"Tang","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"issue":"3","key":"2025121103123462600_ref75","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"2025121103123462600_ref76","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/bs.irn.2020.02.006","article-title":"The impact of neurovascular, blood-brain barrier, and glymphatic dysfunction in neurodegenerative and metabolic diseases","volume":"154","author":"Braun","year":"2020","journal-title":"Int Rev Neurobiol"},{"issue":"3","key":"2025121103123462600_ref77","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2174\/1871527316666161205123123","article-title":"Cerebrospinal-fluid Alzheimer\u2019s disease biomarkers and blood-brain barrier integrity in a natural population of cognitive intact Parkinson\u2019s disease patients","volume":"16","author":"Liguori","year":"2017","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"1","key":"2025121103123462600_ref78","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1186\/1742-2094-9-188","article-title":"Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson\u2019s disease","volume":"9","author":"Pisani","year":"2012","journal-title":"J Neuroinflammation"},{"issue":"2","key":"2025121103123462600_ref79","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3233\/JAD-200168","article-title":"Cerebrospinal fluid\/plasma albumin ratio as a biomarker for blood-brain barrier impairment across neurodegenerative dementias","volume":"75","author":"Musaeus","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2025121103123462600_ref80","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsad198","article-title":"Cerebrospinal-fluid biomarkers for predicting phenoconversion in patients with isolated rapid-eye movement sleep behavior disorder","volume":"47","author":"Fernandes","year":"2024","journal-title":"Sleep"},{"issue":"1","key":"2025121103123462600_ref81","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1","key":"2025121103123462600_ref82","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025121103123462600_ref83","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlx002","article-title":"Regional overlap of pathologies in Lewy body disorders","volume":"76","author":"Colom-Cadena","year":"2017","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"2025121103123462600_ref84","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/JAD-160322","article-title":"Cerebrospinal fluid Alzheimer\u2019s disease biomarkers across the Spectrum of Lewy body diseases: results from a large Multicenter cohort","volume":"54","author":"van Steenoven","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"7691","key":"2025121103123462600_ref85","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"1","key":"2025121103123462600_ref86","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1038\/s41467-024-48961-3","article-title":"Plasma proteomics identify biomarkers predicting Parkinson\u2019s disease up to 7 years before symptom onset","volume":"15","author":"H\u00e4llqvist","year":"2024","journal-title":"Nat Commun"},{"key":"2025121103123462600_ref87","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of microRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O\u2019Brien","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2025121103123462600_ref88","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/jcp.25854","article-title":"Interplay between miRNAs and human diseases","volume":"233","author":"Paul","year":"2018","journal-title":"J Cell Physiol"},{"issue":"10","key":"2025121103123462600_ref89","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41580-020-0251-y","article-title":"RNA delivery by extracellular vesicles in mammalian cells and its applications","volume":"21","author":"O\u2019Brien","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"2025121103123462600_ref90","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nrcardio.2014.207-c1","article-title":"Transport of microRNAs via exosomes","volume":"12","author":"Li","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"2025121103123462600_ref91","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fnagi.2020.00210","article-title":"Increased salivary microRNAs that regulate DJ-1 gene expression as potential markers for Parkinson\u2019s disease","volume":"12","author":"Chen","year":"2020","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"2025121103123462600_ref92","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/mds.27935","article-title":"Salivary microR-153 and microR-223 levels as potential diagnostic biomarkers of idiopathic Parkinson\u2019s disease","volume":"35","author":"Cressatti","year":"2020","journal-title":"Mov Disord"},{"issue":"7","key":"2025121103123462600_ref93","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/cbf.3224","article-title":"Serum miR-221 serves as a biomarker for Parkinson\u2019s disease","volume":"34","author":"Ma","year":"2016","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"2025121103123462600_ref94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41582-021-00598-2","article-title":"Exosomal microRNAs may aid differential diagnosis of movement disorders","volume":"18","author":"Wood","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2025121103123462600_ref95","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41531-023-00628-4","article-title":"Candidate biomarkers of EV-microRNA in detecting REM sleep behavior disorder and Parkinson\u2019s disease","volume":"10","author":"Li","year":"2024","journal-title":"NPJ Parkinsons Dis"}],"container-title":["SLEEPJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsaf174\/63530492\/zsaf174.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/48\/12\/zsaf174\/63530492\/zsaf174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/48\/12\/zsaf174\/63530492\/zsaf174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:12:39Z","timestamp":1765440759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsaf174\/8169703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":95,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6,20]]},"published-print":{"date-parts":[[2025,12,11]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsaf174","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,6,20]]},"article-number":"zsaf174"}}